Indication

Anemia due to chemotherapy and radiotherapy combination

Anemia due to chemotherapy and radiotherapy combination is a secondary hematologic complication characterized by an abnormally low concentration of circulating erythrocytes or hemoglobin in cancer patients receiving concurrent or sequential chemoradiotherapy. Read more about Anemia due to chemotherapy and radiotherapy combination

10 drugs 5 manufacturers

Drugs that treat it

Common Anemia due to chemotherapy and radiotherapy combination therapies.

Showing 10–10 of 10 drugs

Sort

ARANESP (IN POLYSORBATE) (darbepoetin alfa in polysorbate 80)

ERYTHROPOIESIS-STIMULATING AGENTS·CHEMOTHERAPY-INDUCED ANEMIA·+2

AMGEN

Filter & compare in the drug finder →Opens the drug finder with Anemia due to chemotherapy and radiotherapy combination preselected.

News & literature

Coming soon

Related codes

Coming soon

About Anemia due to chemotherapy and radiotherapy combination.

This condition results from compounding toxicities against the hematologic and bone marrow systems, wherein systemic cytotoxic chemotherapy suppresses erythroid progenitor differentiation while radiation directly damages proliferative hematopoietic stem cells within the targeted radiation fields.

Additional contributing factors often include treatment-related nephrotoxicity impairing endogenous erythropoietin production, localized inflammatory cytokine surges, and functional iron deficiency.

Clinically, affected individuals present with manifestations of impaired systemic oxygen transport, including debilitating fatigue, dyspnea on exertion, tachycardia, dizziness, and pale mucous membranes.

cancer.gov
Anemia due to chemotherapy and radiotherapy combination is a secondary hematologic complication characterized by an abnormally low concentration of circulating erythrocytes or hemoglobin in cancer patients receiving concurrent or sequential chemoradiotherapy Clinically, affected individuals present with manifestations of impaired systemic oxygen transport, including debilitating fatigue, dyspnea on exertion, tachycardia, dizziness, and pale mucous membranes
nih.gov
Anemia due to chemotherapy and radiotherapy combination is a secondary hematologic complication characterized by an abnormally low concentration of circulating erythrocytes or hemoglobin in cancer patients receiving concurrent or sequential chemoradiotherapy Additional contributing factors often include treatment-related nephrotoxicity impairing endogenous erythropoietin production, localized inflammatory cytokine surges, and functional iron deficiency
oncodaily.com
Anemia due to chemotherapy and radiotherapy combination is a secondary hematologic complication characterized by an abnormally low concentration of circulating erythrocytes or hemoglobin in cancer patients receiving concurrent or sequential chemoradiotherapy
dovepress.com
This condition results from compounding toxicities against the hematologic and bone marrow systems, wherein systemic cytotoxic chemotherapy suppresses erythroid progenitor differentiation while radiation directly damages proliferative hematopoietic stem cells within the targeted radiation fields Additional contributing factors often include treatment-related nephrotoxicity impairing endogenous erythropoietin production, localized inflammatory cytokine surges, and functional iron deficiency
healthline.com
This condition results from compounding toxicities against the hematologic and bone marrow systems, wherein systemic cytotoxic chemotherapy suppresses erythroid progenitor differentiation while radiation directly damages proliferative hematopoietic stem cells within the targeted radiation fields Clinically, affected individuals present with manifestations of impaired systemic oxygen transport, including debilitating fatigue, dyspnea on exertion, tachycardia, dizziness, and pale mucous membranes

Personalize your experience

Follow Anemia due to chemotherapy and radiotherapy combination and get updates as they land.

Create a free account

Already a member? Sign in

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it